ATCC

???Anatomy-Physiology-Pharmacology Week in 2025 (APPW2025)??? Discover the novel insights at the seminar and exhibition co-hosted by ATCC and Summit Pharmaceuticals International Corp.! ???Luncheon Seminar: Bridging Disciplines, Fueling Discoveries: The Vital Role of Biological Resources in Life Science Advancements ????Speaker: Ruth R Cheng, PhD (President and CEO of ATCC) ???Date: Monday, March 17, 2025 ???Time: 12:40-13:30 ???Location: Makuhari Messe International Conference Hall, 1st Floor, Room 14 Don't miss out on this groundbreaking event that explores the vital role of biological resources in life science advancements! https://lnkd.in/ek7BxMqT

For more than a century, we’ve supplied the global scientific community with authentic, high-quality biological resources and standards to advance scientific discovery. None of this would be possible without our incredible team of scientists and professionals! Their dedication, passion, and commitment are what drive the future of scientific innovation. In celebration of Employee Appreciation Day, we came together to recognize the team that makes it all happen. Thank you for everything you do! Learn more about joining our incredible team:?https://lnkd.in/e6pbjaBE

Enhance Drug Development with HepatoXcell? ATCC’s HepatoXcell? hepatocytes are meticulously isolated and characterized to support your drug development and toxicity testing needs. With high viability and key liver functions retained, these cells are ideal for various applications including: ? Drug Metabolism & Pharmacokinetics (DMPK) ? Toxicology & Safety Assessment ? Liver Disease Modeling ? Regenerative Medicine & Cell Therapy Discover the difference HepatoXcell? can make in your lab. Visit https://ow.ly/gruR50VfYb2 for more information. #HepatoXcell #ATCC #Biotech #Pharma #ResearchInnovation

Boost your understanding of influenza and avian flu with expert insights! Tomorrow's webinar will cover the latest advancements in diagnostics and control measures. Register now: https://ow.ly/l6kz50VfXwX #Influenza #AvianFlu #Webinar #Diagnostics #ATCC

As ATCC celebrates our 100th year, we are proud to continue collaborating with US Pharmacopeia (USP) to offer the scientific community credible biological products to advance the quality and development of biologic medicines and therapies. USP’s SVP of Legal, Strategy & People, Amanda Cowley, JD, thoughtfully articulates the importance of partnerships like the one between ATCC and USP. Together, we are producing standards that instill confidence in the industry and its regulators while supporting products’ speed to market. We look forward to building on our successes with USP in 2025 and beyond! Learn more about our partnership: https://ow.ly/Gpze50VeaSG

Fatty liver disease has been termed as a silent epidemic affecting over 25% of the global population. However, most of the people affected by non-alcoholic fatty liver disease (NAFLD) remain oblivious as the disease usually manifests at an advanced irreversible stage of non-alcoholic steatohepatitis (NASH). For the treatment of fatty liver and many other liver diseases (e.g., hepatitis) as well as the study of drug metabolism, drug uptake, or liver toxicity of various pharmaceutical and chemical compounds, the best in vitro model is built using primary human hepatocytes. Hepatocytes are the major cell type of liver and are responsible for most of the functions the liver is attributed for, such as the metabolism of food and drugs, synthesis of urea and albumin, removal of toxins, and production of cholesterol. Hence, hepatocytes isolated from the human liver represent the liver functions more accurately than any other cell type and are the gold standard for in vitro liver modeling. ATCC now provides HepatoXcell? primary human hepatocytes for use in disease research and drug discovery. Currently, the HepatoXcell? portfolio offers three different types of primary hepatocytes based on their plate-ability: HepatoXcell? Pro and Plus cells can be cultured for 7 and 3 days, respectively, and HepatoXcell? Eco are suitable for suspension culture. To support the growth and maintenance HepatoXcell? primary human hepatocytes, ATCC also offers three different hepatocyte media: Hepatocyte Thaw Medium helps to enrich viable cells after thawing the cryopreserved hepatocytes, and Hepatocyte Plating Medium and Maintenance Medium enable hepatocyte initiation and maintenance, respectively. Researchers around the globe are now able to use ATCC’s HepatoXcell? hepatocytes for their in vitro hepatic modeling. Learn more: https://ow.ly/1wQs50Vf517

Discover the critical role of diagnostic surveillance in managing influenza outbreaks, and how ATCC’s authenticated reference materials enhance diagnostic accuracy in our latest white paper. Read the whitepaper: https://ow.ly/VOS450VeaVn #Influenza #AvianFlu #Whitepaper #PublicHealth #Research #ATCC

Enhance your understanding of influenza and avian flu with expert insights! Our webinar on Thursday, March 13 at 12 PM ET will cover the latest advancements in diagnostics development. Don't miss out! Register now: https://ow.ly/NEVu50Vc0X0 #Influenza #AvianFlu #Webinar #Diagnostics #ATCC

ATCC's toxicology products are at the forefront of advancing scientific research and ensuring safety in various industries. Read the next post in our 100 for 100 series to learn about our featured cell models for toxicology. Read the blog: https://ow.ly/psXK50VblZI #CredibleConversations